Work Here?
About Arcellx
Industries
Biotechnology
Healthcare
Company Size
51-200
Company Stage
IPO
Headquarters
Gaithersburg, Maryland
Founded
2014
Overview
Arcellx develops immunotherapies aimed at transforming cell therapy for serious diseases. The company focuses on creating proprietary products that utilize advanced cell therapy techniques. Their approach involves extensive research and development to ensure the safety and effectiveness of their treatments. Arcellx differentiates itself from competitors by concentrating on unmet medical needs and forming partnerships and licensing agreements to support their commercialization efforts. The ultimate goal of Arcellx is to provide innovative treatment options that improve patient outcomes in the healthcare sector.
Simplify's Take
What believers are saying
- Global CAR-T market projected to grow at 34.5% CAGR until 2030.
- FDA's support for fast-tracking therapies benefits Arcellx's product approvals.
- Partnerships with Kite enhance Arcellx's research and development capabilities.
What critics are saying
- Intensifying competition from companies like Bristol-Myers Squibb and Johnson & Johnson.
- High development costs may limit accessibility of Arcellx's therapies.
- Reliance on partnerships exposes Arcellx to partner performance risks.
What makes Arcellx unique
- Arcellx's CART-ddBCMA has FDA Fast Track and Orphan Drug designations.
- ARC-SparX offers dosable and controllable CAR-T therapy options.
- Anito-cel uses a novel D-Domain BCMA binder for enhanced cell killing.
Help us improve and share your feedback! Did you find this helpful?
Funding
Total Funding
$628.8M
Above
Industry Average
Funded Over
4 Rounds
New Enterprise AssociatesBenefits
Health Insurance
Dental Insurance
Vision Insurance
Unlimited Paid Time Off
Flexible Work Hours
401(k) Company Match
Fully-Paid Parental Leave
Tuition Reimbursement
Relocation Assistance
Growth & Insights and Company News
6 month growth
↓ -2%1 year growth
↑ 0%2 year growth
↑ 2%Arcellx appoints Andrew Galligan and Kristin Myers to its Board of Directors.
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases, today announced that management will participate in a fireside chat at the TD Cowen 45th Annual Health Care Conference on Wednesday, March 5, at 1:10 p.m. ET.A live webcast of this discussion will be accessible from Arcellx’s website at www.arcellx.com in the Investors section. A replay of the webcast will be archived and available for 30 days following the event.About Arcellx, Inc.Arcellx, Inc. is a clinical-stage biotechnology company reimagining cell therapy by engineering innovative immunotherapies for patients with cancer and other incurable diseases. Arcellx believes that cell therapies are one of the forward pillars of medicine and Arcellx’s mission is to advance humanity by developing cell therapies that are safer, more effective, and more broadly accessible
REDWOOD CITY, Calif. SANTA MONICA, Calif.--(BUSINESS WIRE)--Arcellx, Inc. (NASDAQ: ACLX) and Kite, a Gilead Company (NASDAQ: GILD), today announced several key operational updates on their partnered anitocabtagene autoleucel (anito-cel) multiple myeloma program. Anito-cel is the first BCMA CAR T to be investigated in multiple myeloma that utilizes Arcellx’s novel and compact D-Domain binder. The companies shared the design of a global, Phase 3 randomized controlled clinical trial, iMMagine-3, which Kite expects to start in the second half of this year. The trial will compare the efficacy and safety of anito-cel randomized against the standard of care (SOC) in patients with relapsed and/or refractory multiple myeloma (rrMM) who have received one to three prior lines of therapy, including an immunomodulatory drug (lMiD) and an anti-CD38 monoclonal antibody
REDWOOD CITY, Calif. SANTA MONICA, Calif.--(BUSINESS WIRE)--Kite, a Gilead Company (NASDAQ: GILD), and Arcellx, Inc. (NASDAQ: ACLX) today announced several key operational updates on their partnered anitocabtagene autoleucel (anito-cel) multiple myeloma program. Anito-cel is the first BCMA CAR T to be investigated in multiple myeloma that utilizes Arcellx’s novel and compact D-Domain binder. The companies shared the design of a global, Phase 3 randomized controlled clinical trial, iMMagine-3, which Kite expects to start in the second half of this year. The trial will compare the efficacy and safety of anito-cel randomized against the standard of care (SOC) in patients with relapsed and/or refractory multiple myeloma (rrMM) who have received one to three prior lines of therapy, including an immunomodulatory drug (lMiD) and an anti-CD38 monoclonal antibody
Arcellx, Inc. (NASDAQ:ACLX) just released its full-year report and things are looking bullish.
Arcellx is Hiring for 31 Jobs on Simplify!
Find jobs on Simplify and start your career today
About Arcellx
Industries
Biotechnology
Healthcare
Company Size
51-200
Company Stage
IPO
Headquarters
Gaithersburg, Maryland
Founded
2014
Arcellx is Hiring for 31 Jobs on Simplify!
Find jobs on Simplify and start your career today